CBR3: A Potential Drug Target and Biomarker for Chronic Pain (G874)

Target Name: CBR3

NCBI ID: G874

CBR3

CBR3: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with 30% of these individuals being in extreme pain. Chronic pain can be caused by various conditions, including neuropathic pain, rheumatoid arthritis, and cancer pain. These conditions can be debilitating and greatly impacting an individual's quality of life.

CBR3, a protein known as quinone reductase, has been identified as a potential drug target and biomarker for chronic pain. CBR3 is a key enzyme in the production of 9-carboxy-dehydroepinephrine (9-DEP), a compound that has been shown to have neuroprotective properties in various experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and neurofibromatosis.

CBR3 function

CBR3 is a member of the superfamily of NAD+-dependent enzymes, known as NAD+-dependent enzymes. These enzymes use NAD+ as a cofactor to reduce coenzyme A to its reduced form, A. The NAD+-dependent enzymes have been implicated in various cellular processes, including DNA replication, metabolism, and signaling pathways.

CBR3 is involved in the production of 9-DEP, which is a key metabolite of the pain-modulatory molecule, endocannabinoids. 9-DEP has been shown to have neuroprotective properties, including an anti-inflammatory effect and a neuro-relaxant effect. CBR3-mediated production of 9-DEP may contribute to the neuroprotective effects of 9-DEP in experimental models of chronic pain.

CBR3 as a drug target

The potential drug target for CBR3 is based on its involvement in the production of 9-DEP, which has been shown to have neuroprotective properties. Drugs that can inhibit CBR3 activity and reduce 9-DEP levels may be effective in treating chronic pain.

One approach to targeting CBR3 is to use small molecules that can inhibit the activity of CBR3. A variety of compounds have been shown to inhibit CBR3 activity, including inhibitors of the NAD+-dependent redox states that are generated by CBR3.

Another approach to targeting CBR3 is to use RNA interference (RNAi) to knockdown CBR3 expression in target cells. This approach can be used to identify potential drug targets for CBR3 and to study its function in specific cellular processes.

CBR3 as a biomarker

CBR3 may also be used as a biomarker for chronic pain. The production of 9-DEP by CBR3-mediated metabolism can be quantified and used as a marker for the activity of CBR3. The levels of 9-DEP can be measured in patient samples, providing a potential biomarker for chronic pain.

Conclusion

CBR3 is a protein that has been identified as a potential drug target and biomarker for chronic pain. Its involvement in the production of 9-DEP, a compound with neuroprotective properties, makes CBR3 a promising target for the development of new treatments for chronic pain. The use of small molecules and RNAi to inhibit CBR3 activity may lead to the development of new treatments for chronic pain. Further research is needed to fully understand the role of CBR3 in chronic pain and to develop effective treatments.

Protein Name: Carbonyl Reductase 3

Functions: Catalyzes the NADPH-dependent reduction of carbonyl compounds to their corresponding alcohols (PubMed:18493841). Has low NADPH-dependent oxidoreductase activity. Acts on several orthoquinones, acts as well on non-quinone compounds, such as isatin or on the anticancer drug oracin (PubMed:18493841, PubMed:15537833, PubMed:19841672). Best substrates for CBR3 is 1,2- naphthoquinone, hence could play a role in protection against cytotoxicity of exogenous quinones (PubMed:19841672). Exerts activity toward ortho-quinones but not paraquinones. No endogenous substrate for CBR3 except isatin has been identified (PubMed:19841672)

The "CBR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets